GEN1046 as a Single Agent or in Combination With Pembrolizumab · Recurrent (Non-small Cell) Lung Cancer
Trial terminated
GenmabPhase 2 NCT05117242 Registry history of NCT05117242 on ClinicalTrials.gov (opens the registry)
10 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 6 with minor changes only.
Trial terminated
GenmabPhase 2 NCT05117242 Registry history of NCT05117242 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 4 → 5
GenmabPhase 1/2 NCT05579366 Registry history of NCT05579366 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 15, 2026 to Oct 15, 2026
Also in this update: Trial sites expanded: 1 → 4 locations; and 1 more change in the last 30 days
GenmabPhase 3 NCT07775287 Registry history of NCT07775287 on ClinicalTrials.gov (opens the registry)
Results posted: Sep 30, 2026
GenmabPhase 2 NCT06984328 Registry history of NCT06984328 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 2 → 9 locations
GenmabPhase 3 NCT07564141 Registry history of NCT07564141 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 22 → 34 locations
GenmabPhase 3 NCT07225270 Registry history of NCT07225270 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 171 → 177 locations
GenmabPhase 3 NCT07166094 Registry history of NCT07166094 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 74 → 91 locations
GenmabPhase 2 NCT07288177 Registry history of NCT07288177 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 17 locations
GenmabPhase 2 NCT07539311 Registry history of NCT07539311 on ClinicalTrials.gov (opens the registry)
Final enrollment: 584 participants (planned 530)
Also in this update: Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026; Study completion moved earlier from May 23, 2028 to Oct 2027
GenmabPhase 3 NCT06619236 Registry history of NCT06619236 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-05 | NCT07859215 Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 6 | |
| Phase 1/2 | 7 | |
| Phase 2 | 4 | |
| Phase 3 | 15 |
Non-Hodgkin Lymphoma (13) · DLBCL (10) · Ovarian Cancer (6) · Follicular Lymphoma (5) · Leukemia (5) · Lung Cancer (4) · Non-Small Cell Lung Cancer (NSCLC) (4) · Chronic Lymphocytic Leukemia (CLL) (3) · Colorectal Cancer (3) · Endometrial Cancer (2)